|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Editorial: Too Strict at NIH
The Post notes that under the NIH’s new conflict of interest rules “all of [its] 17,500 employees—and their spouses and minor children—would be barred from owning more than $15,000 worth of stock in a wide variety array of drugmakers, biotechnology firms, and manufacturers of medical devices. Moreover, at least one-third of the NIH workforce—scientists at a senior enough level that they have to file confidential financial disclosure forms, and those involved in dispensing grants—would be prohibited, along with their families, from holding any stock in such firms.”
The Post argues that “an across the board ban in situations in which there is no possibility of even an appearance of conflict goes too far.”
What else is there left to say?
|home spotlight commentary research events news about contact links archives|